RxDoctor Payments Data

Wilmer Valentin, MD

General Practice · Porter, TXNPI 1174960967

Payments from drug & device makers

$1,519in general payments, 2019–2025

Across 80 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$403
  • Lilly USA, LLC$194
  • GSK$148
  • AstraZeneca$132
  • Astellas Pharma US Inc$107
  • Shield Therapeutics Inc$105
  • plus $429 from 11 others

What the payments were for

  • Food & beverage$1,41093%
  • Education$1087%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,519 in reported general payments places this provider in the 85th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas

Medicare billing

Part B allowed, 2024
$914,956
Medicare patients
126
Services billed
1,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide37$37,832
OzempicSemaglutide30$33,176
JanuviaSitagliptin Phosphate38$31,156
EliquisApixaban23$20,447
TrulicityDulaglutide12$17,576
LinzessLinaclotide16$14,736
UbrelvyUbrogepant12$12,469
TradjentaLinagliptin13$9,515
Breo ElliptaFluticasone/Vilanterol11$7,015
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$4,828
Atorvastatin Calcium236$1,954
Gabapentin97$1,930
Levothyroxine Sodium146$1,922
Nifedipine ErNifedipine60$1,866
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$1,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$194$55,40949 claims
Novo NordiskOzempic$403$33,17630 claims
AbbVieLinzess, Ubrelvy$44$27,20628 claims
Boehringer IngelheimTradjenta$45$9,51513 claims
GSKBreo Ellipta$148$7,01511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,074 general practice providers in Texas.

Other general practice in Porter

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →